Potential theranostic approach of 177Lu-trastuzumab and 177Lu-FAPI in metastatic breast cancer: An ongoing study

被引：0
|
作者：
Assadi, M. [1 ]
Rekabpour, S. [1 ]
Jokar, N. [1 ]
Ahmadzadehfar, H. [2 ]
Jafari, E. [1 ]
机构：
[1] Bushehr Univ Med Sci BUMS, Bushehr, Iran
[2] Klinikum Westfalen, Dept Nucl Med, Dortmund, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0815
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [41] 177Lu-5-Fluorouracil a potential theranostic radiopharmaceutical: radiosynthesis, quality control, biodistribution, and scintigraphy
    Rasheed, Rashid
    Tariq, Saleha
    Naqvi, Syed Ali Raza
    Gillani, Syed Jawad Hussain
    Rizvi, Faheem Askari
    Sajid, Muhammad
    Rasheed, Shahid
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2016, 59 (10): : 398 - 403
  • [42] Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
    Ritt, Philipp
    Nicolai, Heinz
    Fernandez, Rene
    Soza-Ried, Cristian
    Amaral, Horacio
    Krieger, Korbinian
    Mapanao, Ana Katrina
    Rotger, Amanda
    Zhernosekov, Konstantin
    Schibli, Roger
    Mueller, Cristina
    Kramer, Vasko
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [43] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [44] Dual 177Lu-Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation
    Beyhan, Ediz
    Fenercioglu, Ozge Erol
    Sahin, Rahime
    Cermik, Tevfik Fikret
    Ergul, Nurhan
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (05) : 447 - 448
  • [45] 177Lu-LHRH analog as a potential prostate cancer theragnostic agent
    Camacho, Ximena
    Alfaya, Lucia
    Perroni, Carolina
    Tassano, Marcos
    Cabrera, Mirel
    Reyes, Ana
    Paolino, Andrea
    Fernandez, Marcelo
    Cerecetto, Hugo
    Savio, Eduardo
    Duarte, Pablo
    Cabral, Pablo
    Gambini, Juan
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [46] Pre-therapeutic dosimetry of 177Lu-rhPSMA7.3 and 177Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer
    Feuerecker, B.
    Chantadisai, M.
    Allmann, A.
    Tauber, R.
    Allmann, J.
    Wester, H.
    Weber, W. A.
    D'Alessandria, C.
    Eiber, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S381 - S381
  • [47] An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
    Rinscheid, Andreas
    Gaeble, Alexander
    Wienand, Georgine
    Pfob, Christian
    Dierks, Alexander
    Kircher, Malte
    Trepel, Martin
    Weckermann, Dorothea
    Lapa, Constantin
    Bundschuh, Ralph A.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (12) : 1918 - 1924
  • [48] Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma
    Dadgar, Habibollah
    Jafari, Esmail
    Ahmadzadehfar, Hojjat
    Rekabpour, Seyed Javad
    Ravanbod, Mohammad Reza
    Kalantarhormozi, Mohammadreza
    Nabipour, Iraj
    Assadi, Majid
    ANNALES D ENDOCRINOLOGIE, 2023, 84 (01) : 45 - 51
  • [49] Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F(ab′)2-trastuzumab for theranostic agent of HER2 positive breast cancer
    Hermanto, Sandra
    Haryuni, Ratna Dini
    Ramli, Martalena
    Mutalib, Abdul
    Hudiyono, Sumi
    JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, 2016, 9 (04) : 441 - 448
  • [50] 177 Lu-EDTMP for Bone Pain Palliation in Metastatic Prostate and Breast Cancer: a phase II trial
    Liu, X.
    Liu, C.
    Li, H.
    Luo, Z.
    Wang, Y.
    John, Z. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S225 - S225
12345